Company / Free Cash Flow
Whitehawk Therapeutics, Inc. Free Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$61.2M
FY2025
5-year range
-$63.6M / -$12.7M
FY2021-FY2025
Trend
+3.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow returned to growth in FY2025 after 3 years of decline, reaching -$61M.
Based on SEC 10-K filings.
-$61M in FY2025.
Declined from -$50M to -$61M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 3.8% year-over-year.
- Peak free cash flow was recorded in FY2019.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$61.2M | +3.8% |
| FY2024 | -$63.6M | -27.1% |
| FY2023 | -$50.1M | -122.9% |
| FY2022 | -$22.5M | -76.3% |
| FY2021 | -$12.7M | +47.1% |
| FY2020 | -$24.1M | -312.1% |
| FY2019 | -$5.8M | +69.1% |
| FY2018 | -$18.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026